Rimegepant orally disintegrating tablet 75  mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial

ConclusionsA single dose of rimegepant 75  mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo.Trial registration Clinicaltrials.gov NCT04574362  Date registered: 2020-10-05.Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research